Grifols successfully completes Biotest delisting

Barcelona, Spain, June 11, 2025.- Grifols (MCE: GRF, MCE: GRF.P NASDAQ: GRFS), a global healthcare company and leading producer of plasma-derived medicines, today announced it has successfully completed the delisting of its German subsidiary Biotest AG, after increasing its stake in Biotest’s share capital to 80.32%. The transaction entailed the acquisition of 416,922 ordinary shares, at 43,00 euros per share, and 3,002,804 preferred shares, at 30,00 euros per share, for a total cost of 108 million euros. As a result, Grifols significantly increases its stake in Biotest AG, to 99.25% of the voting rights and 61.40% of the preferred shares.

As a result, Grifols has met its objective of delisting Biotest, following approval from the Frankfurt Stock Exchange on June 6.

For Nacho Abia, Grifols CEO: "Increasing our stake in Biotest while remaining highly disciplined and delisting Biotest is a part of our strategic plan. We continue to focus on our deleveraging and free cash flow improvement priorities."